Vitiligo pathogenesis is driven by signalling through Janus kinase (JAK) 1 and 2. In a clinical trial, topical ruxolitinib cream produced substantial facial and total body repigmentation up to 1 year .
Vitiligo is a chronic autoimmune disease of the skin that targets melanocytes, resulting in patches of skin depigmentation . Expression of interferon (IFN)-γ is increased in the lesional skin of patients. Neutralisation of IFN-γ prevents CD8(+) T-cell accumulation and depigmentation, suggesting a therapeutic potential for this approach . Thus, JAK1/JAK2 inhibitors appear effective in vitiligo, presumably via inhibition of IFN-γ signalling in the skin .
Ruxolitinib cream across a dose range of 0.15 to 1.5% provided significant repigmentation of facial vitiligo lesion after 24 weeks of double-blind, vehicle-controlled treatment . After the blinded study phase, all patients were re-randomised and then treated with 1.5% ruxolitinib cream fo...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« 20-year follow-up of imatinib in chronic myeloid leukaemia Next Article
Green light for a second JAK inhibitor in AD »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.